Watanabe Jun, Kakehi Eiichi, Kotani Kazuhiko, Kayaba Kazunori, Nakamura Yosikazu, Ishikawa Shizukiyo
1Division of Community and Family Medicine, Center for Community Medicine, Jichi Medical University, 3311-1 Yakushiji, Shimotsuke, Tochigi 329-0498 Japan.
Department of General Medicine, Tottori Municipal Hospital, 1-1 Matoba, Tottori, Tottori Japan.
Diabetol Metab Syndr. 2019 Jan 9;11:3. doi: 10.1186/s13098-018-0398-2. eCollection 2019.
Metabolic syndrome (MetS) and cancer are major public health problems worldwide. The relationship between MetS and cancer death is of great interest. We examined the predictive value of MetS for cancer mortality in Japan.
Study participants included 4495 men and 7028 women aged 18-90 years who were registered between 1992 and 1995 as part of the Jichi Medical School Cohort Study. We used a definition of MetS modified for the Japanese population. The primary outcome was cancer mortality. Additionally, the relationship between MetS and cancer-type specific mortality was examined. Analyses were conducted with Cox's regression models adjusted for age, smoking status, alcohol drinking status, marital status, educational attainment, physical activity, occupational category, and menopausal status (only in women).
During a mean follow-up of 18.5 years, 473 men and 297 women died from cancer. MetS was positively associated with cancer mortality in women (hazard ratio [HR], 1.69; 95% confidence interval [CI] 1.21-2.36), but not in men (HR, 1.21; 95% CI 0.90-1.62). Additionally, MetS was associated with a high risk of colorectal (HR, 3.48; 95% CI 1.68-7.22) and breast (HR, 11.90; 95% CI 2.25-62.84) cancer deaths in women.
MetS was a significant predictor of cancer mortality in women.
代谢综合征(MetS)和癌症是全球主要的公共卫生问题。MetS与癌症死亡之间的关系备受关注。我们研究了MetS对日本癌症死亡率的预测价值。
研究参与者包括4495名年龄在18 - 90岁之间的男性和7028名女性,他们于1992年至1995年登记参加了自治医科大学队列研究。我们采用了针对日本人群修改后的MetS定义。主要结局是癌症死亡率。此外,还研究了MetS与特定癌症类型死亡率之间的关系。分析采用Cox回归模型,并对年龄、吸烟状况、饮酒状况、婚姻状况、教育程度、身体活动、职业类别和绝经状态(仅针对女性)进行了调整。
在平均18.5年的随访期间,473名男性和297名女性死于癌症。MetS与女性癌症死亡率呈正相关(风险比[HR],1.69;95%置信区间[CI] 1.21 - 2.36),但与男性无关(HR,1.21;95% CI 0.90 - 1.62)。此外,MetS与女性结直肠癌(HR,3.48;95% CI 1.68 - 7.22)和乳腺癌(HR,11.90;95% CI 2.25 - 62.84)死亡风险较高有关。
MetS是女性癌症死亡率的重要预测指标。